BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36610231)

  • 1. Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
    Lassche G; van Engen-van Grunsven ACH; van Hooij O; Aalders TW; Am Weijers J; Cocco E; Drilon A; Hoischen A; Neveling K; Schalken JA; Verhaegh GW; van Herpen CML
    Oral Oncol; 2023 Feb; 137():106297. PubMed ID: 36610231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
    Bell D; Ferrarotto R; Liang L; Goepfert RP; Li J; Ning J; Broaddus R; Weber RS; El-Naggar AK
    Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ; Lee YH; Jin YT; Hsieh MS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-grade salivary gland carcinoma with the ETV6-NTRK3 gene fusion: A case report and literature review of secretory carcinoma with high-grade transformation.
    Asai S; Sumiyoshi S; Yamada Y; Tateya I; Nagao T; Minamiguchi S; Haga H
    Pathol Int; 2021 Jun; 71(6):427-434. PubMed ID: 33848386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
    Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
    Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
    Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
    Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretory Carcinoma of the Salivary Gland: A Rarity in Children.
    Kelly GA; Venkatramani R; Quintanilla NM; Chelius DC; Roy A; Mahajan P
    J Pediatr Hematol Oncol; 2022 May; 44(4):167-172. PubMed ID: 34486543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.
    Skálová A; Vanecek T; Sima R; Laco J; Weinreb I; Perez-Ordonez B; Starek I; Geierova M; Simpson RH; Passador-Santos F; Ryska A; Leivo I; Kinkor Z; Michal M
    Am J Surg Pathol; 2010 May; 34(5):599-608. PubMed ID: 20410810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature.
    Luo W; Lindley SW; Lindley PH; Krempl GA; Seethala RR; Fung KM
    Int J Clin Exp Pathol; 2014; 7(12):9008-22. PubMed ID: 25674280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion.
    Skálová A; Banečkova M; Thompson LDR; Ptáková N; Stevens TM; Brcic L; Hyrcza M; Michal M; Simpson RHW; Santana T; Michal M; Vaněček T; Leivo I
    Am J Surg Pathol; 2020 Oct; 44(10):1295-1307. PubMed ID: 32675658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to the diagnosis of secretory carcinoma of the salivary glands: a case series and review.
    Hermann CR; Gama-Cuellar AG; Díaz KP; Gondak R
    Gen Dent; 2023; 71(2):23-27. PubMed ID: 36825969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
    Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
    Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
    Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
    Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family.
    Guilmette J; Dias-Santagata D; Nosé V; Lennerz JK; Sadow PM
    Hum Pathol; 2019 Jan; 83():50-58. PubMed ID: 30130630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
    Suzuki K; Harada H; Takeda M; Ohe C; Uemura Y; Kawahara A; Sawada S; Kanda A; Sengupta B; Iwai H
    BMC Med Genomics; 2022 Jan; 15(1):6. PubMed ID: 34991563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
    Florou V; Nevala-Plagemann C; Whisenant J; Maeda P; Gilcrease GW; Garrido-Laguna I
    J Natl Compr Canc Netw; 2021 May; 19(5):478-482. PubMed ID: 34030125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
    Bishop JA; Yonescu R; Batista D; Begum S; Eisele DW; Westra WH
    Hum Pathol; 2013 Oct; 44(10):1982-8. PubMed ID: 23773480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.